Kaitlin M. Kestenberg-Messina - Aug 30, 2024 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Signature
/s/ Kaitlin M. Kestenberg-Messina, by Adam S. Grossman as Attorney-in-fact
Stock symbol
ADMA
Transactions as of
Aug 30, 2024
Transactions value $
-$408,050
Form type
4
Date filed
8/30/2024, 09:05 PM
Previous filing
Jul 26, 2024
Next filing
Oct 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Options Exercise $19.1K +8.13K +1.81% $2.35 457K Aug 30, 2024 Direct
transaction ADMA Common Stock Options Exercise $11.3K +4.38K +0.96% $2.59 462K Aug 30, 2024 Direct
transaction ADMA Common Stock Options Exercise $39.5K +6.65K +1.44% $5.94 468K Aug 30, 2024 Direct
transaction ADMA Common Stock Options Exercise $23.6K +5K +1.07% $4.72 473K Aug 30, 2024 Direct
transaction ADMA Common Stock Sale -$408K -24.2K -5.1% $16.90 449K Aug 30, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Common Stock Options Exercise -$19.1K -8.13K -68.42% $2.35 3.75K Aug 30, 2024 Common Stock 8.13K $2.35 Direct F4
transaction ADMA Common Stock Options Exercise -$11.3K -4.38K -100% $2.59 0 Aug 30, 2024 Common Stock 4.38K $2.59 Direct F5
transaction ADMA Common Stock Options Exercise -$39.5K -6.65K -100% $5.94 0 Aug 30, 2024 Common Stock 6.65K $5.94 Direct F6
transaction ADMA Common Stock Options Exercise -$23.6K -5K -100% $4.72 0 Aug 30, 2024 Common Stock 5K $4.72 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $16.72 to $17.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2 Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to
F3 (continued from footnote 2) the reporting person's continued service as of the applicable vesting date; (v) 12,500 unvested RSUs granted on September 28, 2021, which are the remaining unvested RSUs of the 100,000 RSUs granted on September 28, 2021 which vest on a schedule of 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vii) 125,518 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F4 These options were granted on February 25, 2021 and will vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years thereafter, subject to the reporting person's continued service as of the applicable vesting date, and will become fully vested on February 25, 2025.
F5 These options were granted on March 10, 2020 and are fully vested.
F6 These options were granted on October 9, 2018 and are fully vested.
F7 These options were granted on May 3, 2018 and are fully vested.